Editas Medicine,Inc. (NASDAQ:EDIT) Files An 8-K Results of Operations and Financial ConditionItem 2.02.Results of Operations and Financial Condition
On August 9, 2017, Editas Medicine, Inc., a Delaware corporation (the “Company”), issued a press release announcing financial results for the fiscal quarter ended June 30, 2017 and other business highlights. A copy of the press release is being furnished as Exhibit99.1 to this Current Report on Form8-K.
The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 2.02.Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No.
|
Description
|
|
99.1
|
Press release issued by the Company on August 9, 2017*
|
*This exhibit shall be deemed to be furnished and not filed.
Editas Medicine, Inc. ExhibitEX-99.1 2 ex-99d1.htm EX-99.1 edit_Ex99_1 Exhibit 99.1 Editas Medicine Announces Second Quarter 2017 Results and Update Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT‑101 made significant progress toward clinical trials Achieved research milestone in Juno Therapeutics,…To view the full exhibit click here
About Editas Medicine,Inc. (NASDAQ:EDIT)
Editas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology. CRISPR/Cas9 uses a protein ribonucleic acid (RNA) complex consisting of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence that requires repair. The Company has initiated a range of research programs across multiple therapeutic areas. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs, including Non-malignant Hematologic Diseases, Duchenne Muscular Dystrophy, Cystic Fibrosis and Alpha-1 Antitrypsin Deficiency.